Cancer Stem Cell News Volume 3.36 | Sep 17 2014

    0
    353
    Cancer Stem Cell News 3.36 September 17, 2014

    Cancer Stem Cell News

         In this issue: Publications | Reviews | Science News | Industry News | Policy News | Events | Jobs
    Cell Therapy News on Facebook  CSCN on Twitter

     
    TOP STORY
    MicroRNA100 Inhibits Self-Renewal of Breast Cancer Stem-Like Cells and Breast Tumor Development
    Scientists report evidence implicating the microRNA100 (miR-100) in self-renewal of cancer stem-like cells. They found that miR-100 expression levels relate to the cellular differentiation state with lowest expression in cells displaying stem cell markers. [Cancer Res] Abstract
    View Data: StemSpanâ„¢ SFEM II Serum-Free Medium

     
    PUBLICATIONS (Ranked by impact factor of the journal)
    Targeting Proapoptotic Protein BAD Inhibits Survival and Self-Renewal of Cancer Stem Cells
    Researchers demonstrate the potential role of proapoptotic protein BAD in the biology of cancer stem cells in melanoma, prostate and breast cancers. [Cell Death Differ] Abstract

    Essential Role of the Cancer Stem/Progenitor Cell Marker Nucleostemin for Indole-3-Carbinol Anti-Proliferative Responsiveness in Human Breast Cancer Cells
    Scientists provide evidence that a natural anti-cancer compound mediates its cellular and in vivo tumor anti-proliferative responses by selectively stimulating cellular interactions of the stem/progenitor cell marker nucleostemin with murine double mutant 2, which frees p53 to trigger its apoptotic response. [BMC Biol] Abstract | Full Article

    The Forkhead Transcription Factor FOXM1 Promotes Endocrine Resistance and Invasiveness in Estrogen Receptor-Positive Breast Cancer by Expansion of Stem-Like Cancer Cells
    Increased expression of FOXM1 was associated with an expansion of the cancer stem-like cell population and with increased cell invasiveness and resistance to endocrine treatments. [Breast Cancer Res]
    Abstract | Full Article

    C-Glycoside Mimetics Inhibit Glioma Stem Cell, Proliferation, Migration and Invasion
    Researchers report the design and synthesis of C-glycoside mimetics subset of the recently published phostines belonging to the [1,2]-oxaphosphinane core. The hit compound 5.3d inhibited invasion and migration on fibronectin, vitronectin and laminin on both GBM stem cells and GBM cancer cell lines. [J Med Chem] Abstract

    miR-152 Functions as a Tumor Suppressor in Glioblastoma Stem Cells by Targeting
    Krüppel-Like Factor 4

    Scientists explored the potential role of miR-152 in glioblastoma stem cells (GSCs) as well as the possible molecular mechanisms. Their results proved that miR-152 was down-regulated in human GSCs. [Cancer Lett] Abstract

    Transient TNF Regulates the Self-Renewing Capacity of Stem-Like Label-Retaining Cells in Sphere and Skin Equivalent Models of Melanoma
    Scientists tested the hypothesis that inflammatory factors affect the cancer stem cell (CSC) compartment responsible for tumor development and relapse. Using an inducible histone 2B-GFP fusion protein as a tracer of cell divisional history, they determined that tumor necrosis factor (TNF), which is a classical pro-inflammatory cytokine, enlarged the CSC pool of GFP-positive label-retaining cells in tumor-like melanospheres. [Cell Commun Signal] Abstract | Full Article

    ALDH1A1 Maintains Ovarian Cancer Stem Cell-Like Properties by Altered Regulation of Cell Cycle Checkpoint and DNA Repair Network Signaling
    Scientists evaluated aldehyde dehydrogenase (ALDH)+ ovarian cancer stem cell-like properties and their role in platinum resistance. Isogenic ovarian cancer cell lines for platinum sensitivity and platinum resistant as well as ascites from ovarian cancer patients were analyzed for ALDH+ by flow cytometry to determine its association to platinum resistance, recurrence and survival. [PLoS One] Full Article

    Esophageal Cancer Stem Cells Express PLGF to Increase Cancer Invasion through MMP9 Activation
    Researchers used a human esophageal cancer cell line, TE-1, to examine the cross talk of placental growth factor (PLGF) and matrix metalloproteinase 9 (MMP9). They found that the levels of PLGF in TE-1 cells positively affected the levels of MMP9, while the levels of MMP9 did not affected the levels of PLGF, suggesting that PLGF may activate MMP9 in esophageal cancer cells. [Tumor Biol] Abstract

    Request Your Free Wallchart: Mesenchymal Stem Cells (A Nature Reviews Molecular Cell Biology Collaboration)

     
    REVIEWS
    Impact of Microenvironment and Stem-Like Plasticity in Cholangiocarcinoma: Molecular Networks and Biological Concepts
    The authors emphasize the dynamic interplay between stem-like intrinsic and tumor microenvironment-extrinsic pathways, which may represent novel options for multi-targeted therapies in cholangiocarcinoma. [J Hepatol] Abstract

    Visit our reviews page to see a complete list of reviews in the cancer stem cell research field.

     
    SCIENCE NEWS
    BioLineRx Presents Positive Preclinical Results in Treatment for AML Patients with FLT3 Mutations
    BioLineRx Ltd. announced the presentation of positive preclinical results of its BL-8040 cancer therapy platform as a novel treatment for a sub-population of acute myeloid leukemia. [Press release from BioLineRx Ltd. discussing research presented at the Society of Hematologic Oncology (SOHO) 2014 Annual Meeting, Houston] Press Release

    From our sponsor:
    View immunology lectures, protocols and other resources on the
    Human Immunology Portal.

     
    INDUSTRY NEWS
    ImmunoCellular Therapeutics Receives Positive Regulatory Feedback on ICT-107 Supporting Advancement to Registrational Phase III Testing in Newly Diagnosed Glioblastoma
    ImmunoCellular Therapeutics, Ltd. provided a corporate update on its plans to advance ICT-107 to a registrational Phase III program in patients with newly diagnosed glioblastoma (GBM), and on its portfolio of dendritic cell-based vaccines: ICT-121 for patients with recurrent GBM; and ICT-140 for patients with ovarian cancer. [ImmunoCellular Therapeutics, Ltd.] Press Release

    Abcodia and BioTime, Inc.’s Subsidiary OncoCyte Corporation to Collaborate on Breast Cancer Diagnostic Development PanC-Dxâ„¢ Markers to be Validated Using Pre-Diagnosis Patient Serum Samples Exclusively Provided by Abcodia
    OncoCyte Corporation and Abcodia Ltd. announced their collaboration focused on the development of OncoCyte’s blood-based PanC-Dxâ„¢ test for early detection of breast cancer. [Abcodia Ltd.] Press Release

     
    POLICY NEWS
    National Institutes of Health (United States)

    Food and Drug Administration (United States)

    Center for Biologics Evaluation and Research (United States)

    European Medicines Agency (European Union)

    Medicines and Healthcare Products Regulatory Agency (United Kingdom)

    Therapeutic Goods Administration (Australia)

     
    EVENTS
    NEW Advances in Cancer Immunotherapies 2014
    October 15-16, 2014
    Singapore, Singapore

    Visit our events page to see a complete list of events in the cancer stem cell community.

     
    JOB OPPORTUNITIES
    NEW Research Assistant or Research Associate – Stem Cell & Cancer Biology (University of North Texas Health Science Center)

    NEW Postdoctoral Fellow – Expression Proteomics and Biomarker Discovery for Clinical Applications (King Faisal Specialist Hospital and Research Centre)

    Postdoctoral Fellow – Cancer and Stem Cell Biology (University of Pennsylvania)

    Postdoctoral Fellow – Stem Cells and Breast Cancer (Albert Einstein College of Medicine in New York)

    Assistant Professor – Cell, Developmental & Cancer Biology (Oregon Health & Science University)

    Postdoctoral Position – Cancer Biology (Yale University School of Medicine)

    Postdoctoral Fellow – Cancer Cell Survival and Proliferation (Washington State University)

    Tenure Track Positions – Cancer Biology (Wake Forest Baptist Medical Center)

    Scientist – Pluripotent Stem Cell Media Development, High Throughput Screening (STEMCELL Technologies Inc.)

    Scientist – Cell Culture Support Products (STEMCELL Technologies Inc.)

    Scientist – Immunology/Cell Separation (STEMCELL Technologies Inc.)

    Recruit Top Talent: Reach more than 50,000 potential candidates by posting your organization’s career opportunities on the Connexon Creative Job Board at no cost.

     

    Have we missed an important article or publication in Cancer Stem Cell News? Click here to submit!

    Comments or suggestions? Submit your feedback here

    Learn more about Cancer Stem Cell News: Archives | Events | Contact Us